Paper
Inhibition of Histamine Synthesis in Brain by α‐Fluoromethylhistidine, a New Irreversible Inhibitor: In Vitro and In Vivo Studies
Published Nov 1, 1980 · M. Garbarg, G. Barbin, E. Rodergas
Journal of Neurochemistry
236
Citations
6
Influential Citations
Abstract
a‐Fluoromethylhistidine (α‐FMH), a new potent inhibitor of histidine decarboxylase (HD), has been used for in vitro and in vivo studies of brain HD. Following a preincubation with (+)‐α‐FMH, brain HD activity was inhibited in a time‐dependent and concentration‐dependent manner. The enzyme activity was not restored by overnight dialysis against standard buffer. The (–) antimer of α‐FMH was ineffective. When injected intraperitoneally in a single dose of 20 mg/kg, (±)‐α‐FMH induced a complete loss in HD activity in cerebral cortex and hypothalamus as well as in peripheral tissues, such as stomach. At a dosage of 100 mg/kg (±)‐α‐FMH did not alter histamine‐N‐methyltransferase, DOPA decarboxylase, and glutamate decarboxylase activities. The maximal decrease of HD activity occurred after 2 h in both cerebral cortex and hypothalamus, but the time course of the recovery of enzyme activity was slower in the cerebral cortex. The enzyme activity reached control value within 3 days in hypothalamus and was not fully restored after 4 days in cerebral cortex. Contrasting with the diminished HD activity, a substantial concentration of histamine remained present in five regions of mouse brain. Thus, α‐FMH is a highly specific irreversible inhibitor of brain HD activity and its efficacy makes it useful to study the physiological role of brain histamine.
a-Fluoromethylhistidine (FMH) is a highly specific and irreversible inhibitor of brain histidine decarboxylase activity, making it useful for studying the physiological role of brain histamine.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...